Citryll and Leading Rheumatology Centres Receive ReumaNederland Grant to Collaborate on NET Research to Advance Novel Treatments for Rheumatoid Arthritis
Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announces a ground-breaking collaboration with leading rheumatology centres of excellence in the Netherlands funded by ReumaNederland (Dutch Arthritis Society).
A Year in Review: An Interview with Citryll’s CEO
Celebrating his first year as CEO of Citryll, Eduardo offers a unique perspective on his journey so far. In this exclusive interview, he reflects on the past year’s challenges, achievements, and strategic initiatives that have driven the company forward.
Citryll Completes Patient Dosing In The Repeat Dose Stage Of The Phase 1 Trial
The Phase 1 first-in-human trial is assessing the safety and tolerability of CIT-013. Part D of the Phase 1 trial is investigating the safety and tolerability of repeat dosing in 9 patient volunteers with rheumatoid arthritis (RA) and 3 healthy volunteers.
Citryll announces the appointment of Maarten Kraan as Chief Medical Officer
Dr. Kraan is a rheumatologist who brings more than 25 years of biopharmaceutical development experience. Dr. Kraan joins Citryll after his CMO role at AM-Pharma. Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.
Citryll announces appointments of Eduardo Bravo as CEO and Tim Schenk as CBO
Mr. Bravo has held multiple CEO positions, including in the autoimmune space, and served as Chair on various Boards.
Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors
Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors.
Citryll Appoints Sjoerd van Gorp as Director of Operations
Sjoerd will work closely with key development partners to expand the therapeutic utilities of CIT-013, its clinical development candidate and derivatives.
Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology
Citryll today announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013.
Citryll enters into bioanalytics partnership with Ardena for the clinical development of CIT-013, antagonist of NET biology and associated pathologies
Citryll’s first in class antibody drug candidate CIT-013 for autoimmune and chronic inflammatory diseases is beginning its bioanalytical phase at Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO).
Citryll Appoints CTO and CSO
Citryll today announces it has appointed Eric Meldrum as Chief Scientific Officer and that current CSO and co-founder Renato Chirivi will transition into the role of Chief Technology Officer.